| 영문 | conception | 한글 | 수태, 임신 |
|---|---|---|---|
| 설명 | 난자가 착상되어 임신이 시작된 것. 임신은 수정으로 시작하여 출산으로 끝난다. 수정은 정자와 난자가 자궁관 내에서 결합하는 것을 이르는 말이며, 임신-성립의 시작이다. 난자는 수정하여 발육을 개시하는 능력이 배란 후 몇 시간 이내이고, 정자는 약 48시간인데, 드물게는 약 1주간이나 유효한 경우도 있으며, 사정 후 2~3시간만에 자궁관의 난소 가까이까지 이른다. 따라서 대개는 정자가 먼저 수정장소(대체로 자궁관의 팽대부)에 가서 대기하다가 난자가 도달하면 정자 중 하나만이 난자와 결합하는 것으로 보고 있다. |
||
| ERPC | evacuation of retained products of conception |
|---|---|
| FDP(s) | 1) Fibrinolytic split Products(= FSP) 2) Fibrinogen Degradation Products |
| FSP | familial spastic paraplegia; fibrin split products; fibrinogen split products; fine suspended partic... |
| REAS | reasonably expected as safe; retained, excluded antrum syndrome |
| RET | reticular; reticulocyte; retina; retention; retained; right esotropia |
| dpc | days post conception |
|---|---|
| AGE | Advanced Glycation End Products |
| AGE | Advanced Glycosylated End-products |
| CPMP | Committee for Proprietary Medicinal Products |
| DPC | Diagnostic Products Corporation |
| conception | <biology, gynaecology> The onset of pregnancy, marked by implantation of the blastocyst, the formation of a viable zygote. Origin: L. Conceptio (18 Nov 1997) |
|---|---|
| imperative conception | A concept that does not arise from association but appears spontaneously and refuses to be banished. (05 Mar 2000) |
| retained menstruation | An accumulation of menstrual blood in the vagina. (12 Dec 1998) |
| retained placenta | Incomplete separation of the placenta and its failure to be expelled at the usual time after delivery of the child. Synonym: incarcerated placenta. (05 Mar 2000) |
| placenta, retained | A placenta which is either adherent or incarcerated by irregular uterine contractions, and which in consequence fails to be expelled after birth. (12 Dec 1998) |
| biological products | Complex pharmaceutical substances, preparations, or agents of organic origin, usually obtained by biological methods or assay, that depend for their action on the processes affecting immunity. They are used especially in diagnosis and treatment of disease (as vaccines or pollen extracts). Biological products are differentiated from biological factors in that the latter are compounds with biological or physiological activity made by living organisms. (12 Dec 1998) |
| blood products | Biopharmaceutical products purified from human blood, such as the blood clotting factor VIII used to treat haemophiliacs. (Recombinant factor VIII is also on the market.) The term also refers to biopharmaceuticals that act on blood or the cells that make blood. These products are often produced by the cells themselves, but in such tiny amounts that extracting them from blood is impractical, and so they are genetically engineered. (14 Nov 1997) |
| gene products, env | Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesised as protein precursors (polyproteins) and later cleaved into the final products by a viral protease. (12 Dec 1998) |
| gene products, gag | Proteins coded by the retroviral gag gene. The products are usually synthesised as protein precursors or polyproteins, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. Gag is short for group-specific antigen. (12 Dec 1998) |
| gene products, nef | Products of the HIV nef gene (formerly 3'-orf gene). The products trans-suppress viral replication and function as negative regulators of transcription. Nef stands for negative factor. (12 Dec 1998) |
| gene products, pol | Retroviral proteins coded by the pol gene. Often synthesised as a gag-pol fusion protein (fusion proteins, gag-pol) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Pol is short for polymerase, the enzyme class of reverse transcriptase. (12 Dec 1998) |
| gene products, rev | Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion. (12 Dec 1998) |
| gene products, rex | Post-transcriptional regulatory proteins required for the accumulation of mRNAs that encode the gag and env gene products in HTLV-I and HTLV-II. The rex (regulator x; x is undefined) products act by binding to elements in the ltr. (12 Dec 1998) |
| gene products, tat | Trans-acting transcription factors. Nuclear proteins whose expression is required for HIV viral replication. The tat protein stimulates HIV-ltr-driven RNA synthesis for both viral regulatory and viral structural proteins. Tat stands for trans-activation of transcription. (12 Dec 1998) |
| gene products, tax | Transcriptional trans-acting proteins of the promoter elements found in the long-terminal repeats (ltr) of HTLV-I and HTLV-II. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the ltr. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|